FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  ROSENWALD LINDSAY A MD
 2. Date of Event Requiring Statement (Month/Day/Year)
11/26/2021		 3. Issuer Name and Ticker or Trading Symbol
Journey Medical Corp [DERM]
(Last)
(First)
(Middle)
C/O JOURNEY MEDICAL CORPORATION,, 9237 E VIA DE VENTURA BLVD., SUITE 105		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

SCOTTSDALE, AZ 85258		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, par value $0.0001 per share 176,470
I
See footnote (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock Warrant (2) 12/15/2017 07/15/2035 Common Stock 500,000 $ 0.596 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
ROSENWALD LINDSAY A MD
C/O JOURNEY MEDICAL CORPORATION,
9237 E VIA DE VENTURA BLVD., SUITE 105
SCOTTSDALE, AZ 85258		   X      

Signatures

/s/ Ramsey Alloush, attorney-in-fact 07/25/2022
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The shares are held by a limited liability company over which the reporting person, as managing member, is deemed to have voting and investment power.
(2) The reporting person holds a warrant with the right to purchase 500,000 shares of common stock, par value $0.0001 per share, of the Issuer. These warrants were granted to Dr. Rosenwald from Fortress Biotech, Inc. pursuant to the Amended and Restated Common Stock Warrant, dated December 12, 2017.
 
Remarks:
This Form 3 is being filed late due to an inadvertent administrative error. Exhibit 24 - Power of Attorney.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.